An interventional study of AMMA Portalbe Scalp Cooling System in Alopecia, Chemotherapy-induced Alopecia and Hair Loss, sponsored by Cooler Heads Care Inc.. Recruiting at 2 sites in United States. Open to female participants aged 21 Years and older. Per ClinicalTrials.gov, last updated 2026-10-22.
Sponsored by Cooler Heads Care Inc. · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 217 studies in Alopecia with a site in United States — 43 open to participants now, 63 under way, 6 of them phase 3. Alopecia · United States.
Among the 217 studies in Alopecia with a site in United States, this one is the 42nd largest by planned enrollment of the 204 interventional ones that give a count, is one of 20 that started in 2024, is one of 93 with no phase, reaches primary completion later than 39 of the 62 other live ones, and was the 147th registered.
512 studies on the registry are indexed under Alopecia; 127 are open to participants now.
Browse Alopecia studies →43 of the 217 studies in Alopecia with a site in United States are open now. Recruiting first, the newest first:
Pelage Pharmaceuticals, Inc. · Sites in United States
Ages 18–65 · Women only
Pelage Pharmaceuticals, Inc. · Sites in United States, Canada
Ages 18–55 · Men only
Johns Hopkins University · Sites in United States
Ages 18–80
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+
University of Miami · Sites in United States
Ages 18+
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 75 Alopecia studies recruiting now, 24 (32%) set no upper age limit and 47 (63%) stop at 75 or younger; 10 take children under 18; 24 take healthy volunteers.
This study: 21 Years and older · female · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
217 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 38 · Phase 2 58 · Phase 3 17 · Phase 4 9
First in 2000; this study’s year is marked. 20 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 99 is above the median of 50 across 431 interventional studies indexed under Alopecia.
Median enrollment 40 across the 204 interventional studies, 204 across the 12 observational. Of the 127 that completed or were terminated, 52 (41%) have results posted.
This tab as a report to print or save as PDF → With an account.
124 of 217 have an industry lead sponsor. The 10 most frequent:
Cooler Heads Care Inc. is the lead sponsor of 2 studies on the registry; 1 is open to participants now.
Cooler Heads Care Inc. has 2 studies filed under Alopecia — fewer than ten, so there is no comparison to draw.
28 of the studies in Alopecia with a site in United States that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06972264Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Males With AGA | 2026-12 |
| NCT07146022Phase 3Veradermics, Inc.Safety and Efficacy of VDPHL01 in Females With Androgenetic Alopecia (AGA) | 2027-06 |
| NCT04207931Wake Forest University Health SciencesTreatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study | 2026-11 |
| NCT05416333Wake Forest University Health SciencesAzelaic Acid as a Novel Treatment for Central Centrifugal Cicatricial Alopecia (CCCA) | 2026-11 |
| NCT07588243CynosureLutronicA Clinical Study to Evaluate the Efficacy and Safety of Ultra in Promoting Hair Regrowth | 2026-12 |
Add all 28 to your calendar (.ics) → With an account.
Among the 217 studies in Alopecia with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this prospective study is to assess the ability of AMMA to prevent hair loss in women receiving chemotherapy (CT) for early-stage breast cancer. Additionally, the purpose is also to assess the safety, tolerability and compliance, quality of life, and satisfaction with hair preservation after CT treatment.
This is a prospectively enrolling, post-market, on-label study to assess the ability of the AMMA PSCS to prevent hair loss in women receiving CT for early-stage breast cancer, and to assess the safety, tolerability and compliance, patient quality of life, and satisfaction with hair after treatment. Female patients at least 21 years of age with stage I, II, or III breast cancer who are receiving a taxane-containing CT regimen that is scheduled to be completed within six months will be identified and data from the electronic health record (EHR) as well as prospective data will be collected.
AMMA is designed to be used by patients in the chemotherapy infusion center, during transport from the infusion center to home, and after arrival at home. Patients will participate in training in AMMA use and will be asked to bring the device to the chemotherapy infusion center for use during each chemotherapy treatment visit. The device will be used for 30 minutes prior to the start of chemotherapy, during chemotherapy and for at least 2.5 hours after chemotherapy. Scalp photos will be obtained at baseline and after the last chemotherapy treatment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
Device: AMMA Portalbe Scalp Cooling System
AMMA Portalbe Scalp Cooling System AMMA is indicated for use in chemotherapy infusion centers, during transit from the infusion center andat home and is intended for use by patients who are undergoing chemotherapy treatment and who want to reduce the likelihood of chemotherapy-induced alopecia.
Hair Loss
To evaluate hair loss as assessed by the investigator at 3 weeks (±1 week) after the completion of the last CT treatment/infusion visit using the Common Terminology Criteria for Adverse Events (CTCAE) post-treatment, by photographs, compared to baseline photographs.
Time frame: 3 Weeks
Device-related adverse events
To assess safety of the AMMA PSCS based on the occurrence of device-related adverse events, occurrence of scalp changes determined by physical examination, and patient symptoms with use of the PSCS.
Time frame: 3 Weeks
Scalp changes
Occurrence of scalp changes in patients during and after use of the AMMA PSCS.
Time frame: 3 Weeks
Patient symptoms
Patient symptoms reported during use of the AMMA PSCS as recorded by a symptom survey following each infusion session.
Time frame: 3 Weeks
Subject's tolerability
Subject's tolerability of AMMA PSCS treatment demonstrated by responses to questions related to tolerability.
Time frame: 3 Weeks
Patient assessment of hair loss
Patient assessment of hair loss as recorded in the Alopecia Self-Report Survey at post-treatment follow-up according to the following scale: \<50% of normal for the patient, or ≥50% hair loss.
Time frame: 3 Weeks
Patient satisfaction and QoL - Body Image Scale (BIS)
Patient satisfaction and QoL as assessed by the BIS at baseline and posttreatment follow-up. The 10-item Body Image Scale was developed by Hopwood et al. in 2001 to measure affective, behavioral, and cognitive body image symptoms. Patients can indicate body image symptoms on a 4-point scale (0 "not at all" to 3 "very much"). The total score ranges from 0 to 30 and can be calculated by summing up the 10 items. A higher score means a higher level of body image disturbance
Time frame: 3 Weeks
Patient satisfaction and QoL - European Organization for Research and Treatment (EORTC) QLQ-BR23
Patient satisfaction and QoL as assessed by the EORTC's QLQ-BR23 at baseline and post-treatment follow-up. All scores are linearly transformed to a 0 to 100 scale. A high or healthy level of functioning is represented by a high functional score. A high QOL is represented by a high score for global health status or QOL. More severe symptoms or problems are represented by high symptom scores or items.
Time frame: 3 Weeks
Device success
Device success is defined as ability to set up and use the AMMA device as instructed. This will be measured for each treatment and then for all treatments. If a study subject does not complete one or more of the CT visits, that does not constitute a device failure.
Time frame: 3 Weeks
Plan to share: No
No publications or documents are linked to this record.
Started Nov 2024 (actual). Primary completion is estimated for Jun 2027, 31 months after the start.
Of 85 non-industry interventional studies with no phase under Alopecia, half reached primary completion within 13 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 46. This study's planned 31 months is above that.
Counting every sponsor, half of 146 studies reached it within 12 months; a quarter within 6 and three quarters within 27.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 22, 2026: primary completion Mar 2026 → Jun 2027 and completion Sep 2026 → Sep 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Cooler Heads Care Inc.